ViroPharma Sets Legal Argument Against FDA Decision On Generic Vancocin
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm, which markets vancomycin hydrochloride, says FDA decision on bioequivalence testing violates FOIA and other statutes.